All In Biotech

NDA 012141 · Baxter Hlthcare

Cytoxan

Cyclophosphamide · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Aug 7, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1959

Nov 16, 1959

Approved uses

2

Original approval plus efficacy supplements

Registered trials

5,442

943 Phase 3, 895 recruiting

FAERS reports

179,390

172,654 serious, 36,268 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 7, 2020.

Cyclophosphamide Tablets is an alkylating drug indicated for treatment of: • Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) • Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. ( 1.2 ) 1.1 Malignant Diseases Cyclophosphamide Tablets is indicated for the treatment of: • malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma • multiple myeloma • leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) • mycosis fungoides (advanced disease) • neuroblastoma (disseminated disease) • adenocarcinoma of the ovary • retinoblastoma • carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. 1.2 Minimal Change Nephrotic Syndrome in Pediatric Patients: Cyclophosphamide Tablets is indicated for the treatment of biopsy proven minimal change nephrotic...

Mechanism: The mechanism of action is thought to involve cross-linking of tumor cell DNA.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 29, 1987 Supplement 37 · Efficacy
  • Nov 16, 1959 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • CYTOXAN · CYCLOPHOSPHAMIDE 25MG · TABLET, ORAL · Prescription
  • CYTOXAN · CYCLOPHOSPHAMIDE 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclophosphamide" as an intervention, any sponsor and status, largest first.

All 5,442 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use16,826
  • febrile neutropenia14,787
  • drug ineffective10,788
  • neutropenia10,780
  • pyrexia9,367
  • disease progression8,229
  • pneumonia6,779
  • thrombocytopenia6,679
  • product use in unapproved indication6,563
  • nausea6,354
  • anaemia6,286
  • sepsis5,803

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,541
20051,760
20061,662
20071,990
20082,643
20093,104
20103,472
20115,665
20125,198
20133,764
20144,002
20155,802
20165,819
20177,870
201811,679
201912,218
202012,590
202112,754
202215,807
202317,132
202417,177
202515,538
202610,200

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9,084 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.